Tirzepatide vs Semaglutide vs Retatrutide

The three-way comparison the obesity-medicine conversation has converged on. Tirzepatide is the dominant clinical product in 2026. Retatrutide is the candidate-to-beat in late-stage development. Semaglutide is now the value tier.

Evidence and pricing are current as of May 2026; new trials may change the picture.

Executive Summary

The GLP-1 receptor agonist class has revolutionized obesity medicine over the past five years, but "GLP-1" as a single category obscures three quite different products. Semaglutide (Wegovy for obesity, Ozempic for T2D) is a single GLP-1 receptor agonist, FDA-approved 2017 for diabetes and 2021 for obesity. Tirzepatide (Zepbound for obesity, Mounjaro for T2D) is a dual GIP/GLP-1 receptor co-agonist, FDA-approved 2022 (diabetes) and 2023 (obesity). Retatrutide is a triple GLP-1/GIP/glucagon receptor co-agonist in Phase 3 development, with Phase 2 data showing the largest weight-loss magnitude of any drug in the class — and the SYNERGY-NASH and TRIUMPH-1 outcomes trials are expected to readout through 2026–2027.

This is a companion to the existing Vanguard monographs on Tirzepatide, semaglutide (within the Next-Generation GLP-1s piece), and the Next-Gen GLP-1 family. This piece is the head-to-head comparison — what the data say when these three are placed directly against each other on weight loss magnitude, cardiovascular outcomes, side-effect profile, and cost-effectiveness.

The honest 2026 framing: tirzepatide is the dominant clinical product. SURMOUNT-5, the first well-powered head-to-head trial against semaglutide, showed 20.2% vs 13.7% weight loss at 72 weeks — a 47% relative advantage that meaningfully changes the clinical case. Retatrutide Phase 2 produced 24.2% weight loss at 48 weeks at the highest dose (12 mg weekly), suggesting another meaningful step up from tirzepatide if Phase 3 confirms. Semaglutide remains the most affordable option with the longest cardiovascular outcomes track record and is the right choice when cost or insurance coverage is the dominant decision factor.

What the evidence supports today:

• Tirzepatide produces approximately 47% larger weight loss than semaglutide head-to-head in SURMOUNT-5 (20.2% vs 13.7% at 72 weeks).
• Retatrutide Phase 2 produced 24.2% weight loss at 48 weeks at the highest tested dose — the largest magnitude of any drug in the class to date.
• Semaglutide has the longest cardiovascular outcomes track record (SUSTAIN-6, SELECT in obesity) and remains the most affordable when paid out of pocket; tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.

Mechanism Differences

All three drugs are synthetic peptide agonists of incretin hormone receptors, but the receptor profiles differ:

• Semaglutide is a pure GLP-1 receptor agonist. The GLP-1 mechanism slows gastric emptying, increases glucose-dependent insulin secretion, suppresses glucagon, and acts centrally to reduce appetite. This was historically the dominant incretin mechanism considered druggable.
• Tirzepatide activates both GLP-1 and GIP receptors. GIP was historically considered redundant or even pro-obesogenic; tirzepatide's clinical success has substantially revised this view. The current understanding is that combined GLP-1 + GIP agonism produces synergistic central appetite suppression, additional adipose and energy expenditure effects, and reduced GI side effects (the GIP component appears to attenuate the nausea that limits single-GLP-1 dose escalation).
• Retatrutide activates GLP-1, GIP, and the glucagon receptor. The glucagon receptor addition is the novel mechanism — glucagon has been historically associated with hyperglycemia (raising blood sugar) but at the doses produced by retatrutide, the dominant effect is increased energy expenditure via increased lipolysis and thermogenesis. The triple agonism produces additional weight loss beyond what tirzepatide achieves in head-to-head simulated comparisons.

Head-to-Head Efficacy

SURMOUNT-5 was the most important head-to-head trial. Roughly 750 adults randomized to tirzepatide or semaglutide at maximum tolerated dose for 72 weeks. Tirzepatide produced 20.2% weight reduction; semaglutide produced 13.7% — a 47% relative advantage for tirzepatide. The trial provides the first well-powered head-to-head comparison of the two leading agents and decisively positions tirzepatide as the more effective option when both are available.

Retatrutide Phase 2 produced 24.2% weight loss at the highest dose at 48 weeks. Cross-trial comparisons should be made cautiously, but the data suggest retatrutide will outperform tirzepatide by a similar margin to that by which tirzepatide outperforms semaglutide — pending Phase 3 confirmation.

Side-Effect Profile Differences

All three drugs share the GLP-1 class side-effect profile — gastrointestinal symptoms (nausea, vomiting, diarrhea, constipation) dominant, especially during dose escalation; rare but real concerns for pancreatitis, gallbladder disease, and (rodent-based) thyroid C-cell signal. Specific patterns differ:

• Semaglutide has the most extensive long-term safety data. GI side effects are common but generally manageable with slow titration. The longer development history means fewer surprises.
• Tirzepatide has slightly lower nausea rates than semaglutide at equivalent weight-loss efficacy — the GIP component appears to attenuate the nausea that limits single-GLP-1 dose escalation. About 6-7% discontinue for GI side effects in SURMOUNT trials.
• Retatrutide Phase 2 showed modest increases in heart rate (4-7 bpm) above tirzepatide baseline — the glucagon agonism appears to increase sympathetic outflow. The clinical significance of this difference is not yet established. GI side effects similar to tirzepatide.

Cost and Access

U.S. retail cash pricing in 2026:

• Semaglutide (Wegovy/Ozempic): ~$1,200-1,400/month brand. Generic semaglutide is approaching but not yet widely available.
• Tirzepatide (Zepbound/Mounjaro): ~$1,000-1,200/month brand.
• Retatrutide: not yet approved, no commercial pricing.

Insurance coverage varies dramatically. Manufacturer copay programs reduce out-of-pocket to $25-550/month for many insured patients. Compounded versions of semaglutide and tirzepatide were widely available during FDA drug shortage designations (now ended for most preparations); compounded retatrutide is not legally available since the drug is not FDA-approved. The gray-market supply chain for compounded GLP-1s carries real quality and identity concerns.

How a Clinician Might Frame the Comparison

• Strongest case for tirzepatide: Most patients in 2026 starting GLP-1 therapy for obesity or T2D, where insurance coverage is acceptable and the patient can afford the medication. Tirzepatide produces meaningfully more weight loss than semaglutide with comparable or better tolerability.
• Strongest case for semaglutide: Patient where cost or insurance coverage favors semaglutide, patient with established cardiovascular disease where the SELECT cardiovascular outcomes data are reassuring, or patient already on stable semaglutide with adequate response who has no specific reason to switch.
• Reasonable case for waiting on retatrutide: Patient at the maximum dose of tirzepatide with inadequate weight loss, willing to wait for retatrutide Phase 3 readout and approval (anticipated 2026-2027). The magnitude of additional benefit may justify waiting.

The three-drug landscape in 2026 has converged on a clear hierarchy: retatrutide > tirzepatide > semaglutide on weight-loss magnitude in head-to-head and cross-trial comparisons. The right choice for an individual patient depends on access, cost, side-effect tolerance, and clinical context. For most patients newly starting GLP-1 therapy in 2026 with appropriate insurance coverage, tirzepatide is the right starting choice.

Educational Disclaimer

This monograph is published by Vanguard Optimization as physician-led, evidence-based education. It is not medical advice. We do not prescribe, diagnose, or establish doctor–patient relationships. Decisions about supplementation or medication should be made with the clinician who knows you and your specific clinical situation. The signal-grading and editorial choices in this document represent our best read of the published literature as of May 2026; new data may change them.

Key References

Aronne LJ, et al. Tirzepatide vs Semaglutide for Weight Loss in Adults with Obesity: SURMOUNT-5. N Engl J Med. 2025.

Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022. (SURMOUNT-1)

Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. (STEP-1)

Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023.

Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023.

Eli Lilly TRIUMPH program clinical trial documents (Phase 3 retatrutide).